{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tuberculosis+Infection%2C+Latent&page=2", "query": { "condition": "Tuberculosis Infection, Latent", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 40, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tuberculosis+Infection%2C+Latent&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tuberculosis+Infection%2C+Latent&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T06:23:42.083Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03886701", "title": "Doravirine, Rifapentine and Isoniazid Interaction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Latent Tuberculosis", "Human Immunodeficiency Virus", "Rifamycins Causing Adverse Effects in Therapeutic Use", "Drug Interaction Potentiation" ], "interventions": [ { "name": "Doravirine (DOR)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Walter K. Kraft", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2019-04-22", "completion_date": "2019-05-20", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886701" }, { "nct_id": "NCT05027958", "title": "Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Healthy", "Latent Tuberculosis Infection (LTBI)" ], "interventions": [ { "name": "Tuberculin Purified Protein Derivative", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 17, "start_date": "2022-05-03", "completion_date": "2024-12-08", "has_results": true, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027958" }, { "nct_id": "NCT04926922", "title": "PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Tuberculosis", "HIV" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 200, "start_date": "2021-07-27", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04926922" }, { "nct_id": "NCT03702049", "title": "Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Latent Tuberculosis Infection" ], "interventions": [ { "name": "Nurse-led Community Health Worker TBI (RN/CHW TBI) program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2019-01-24", "completion_date": "2020-09-04", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03702049" }, { "nct_id": "NCT05766267", "title": "Short-course Regimens for the Treatment of Pulmonary Tuberculosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Tuberculosis, Pulmonary", "Tuberculosis Infection" ], "interventions": [ { "name": "Rifabutin", "type": "DRUG" }, { "name": "Delamanid", "type": "DRUG" }, { "name": "Bedaquiline", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Pyrazinamide", "type": "DRUG" }, { "name": "Isoniazid", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Ethambutol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 288, "start_date": "2023-11-21", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05766267" }, { "nct_id": "NCT01798095", "title": "Equivalence Study of Specificity of PPD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tuberculosis Infection" ], "interventions": [ { "name": "Aplisol@ PPD material", "type": "BIOLOGICAL" }, { "name": "Reference Standard", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "JHP Pharmaceuticals LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 152, "start_date": "2013-02", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-02-25", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Tyler, Texas", "locations": [ { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798095" }, { "nct_id": "NCT07737275", "title": "Screening With Portable X-rays for Rapid Recognition of TB", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tuberculosis (TB)", "Tuberculosis Infection, Latent", "HIV (Human Immunodeficiency Virus)" ], "interventions": [ { "name": "Mobile chest radiography for tuberculosis screening", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2026-08-25", "completion_date": "2028-05-25", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07737275" }, { "nct_id": "NCT05022862", "title": "Economic Incentives and vDOT for Latent Tuberculosis Infection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Latent Tuberculosis" ], "interventions": [ { "name": "Usual Care", "type": "BEHAVIORAL" }, { "name": "Video Directly Observed Therapy alone", "type": "BEHAVIORAL" }, { "name": "Video Directly Observed Therapy plus Financial Incentives", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 399, "start_date": "2022-02-07", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05022862" }, { "nct_id": "NCT02225158", "title": "Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Latent Tuberculosis Infection" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1, "start_date": "2014-08-15", "completion_date": "2017-05-11", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Silver Spring, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02225158" }, { "nct_id": "NCT02771249", "title": "Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infected Population With Latent Tuberculosis" ], "interventions": [ { "name": "rifapentene (RPT)", "type": "DRUG" }, { "name": "darunavir/cobicistat (DRV/c)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2016-06-03", "completion_date": "2021-08-17", "has_results": false, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-10-03T06:23:42.083Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771249" } ] }